{"id":"tak-536ccb","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug combines an ARB (angiotensin II receptor antagonist) component that blocks vasoconstriction and sodium retention with a calcium channel blocker component that reduces vascular smooth muscle contraction. This dual mechanism provides complementary antihypertensive effects with potential for improved efficacy and tolerability compared to monotherapy.","oneSentence":"TAK-536CCB is a dual angiotensin II receptor blocker and calcium channel blocker combination designed to lower blood pressure through multiple mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:41.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT02277691","phase":"PHASE3","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-11-07","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fix-dose combination of Azilsartan and Amlodipine"],"phase":"phase_3","status":"active","brandName":"TAK-536CCB","genericName":"TAK-536CCB","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-536CCB is a small molecule RAF serine/threonine protein kinase inhibitor used in the treatment of Essential Hypertension, specifically Grade I or II Essential Hypertension. It is administered as a tablet, either alone or in combination with other medications such as HCTZ 12.5 mg.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}